
  
    
      
        Introduction_NNP
        In_IN recent_JJ years_NNS ,_, the_DT incidence_NN of_IN breast_NN cancer_NN has_VBZ
        become_VBN one_CD of_IN the_DT most_RBS rapidly_RB increaing_VBG among_IN malignant_JJ
        tumours_NNS ._. With_IN progress_NN in_IN understanding_NN of_IN the_DT nature_NN of_IN
        breast_NN cancer_NN ,_, diagnosis_NN and_CC treatments_NNS have_VBP been_VBN improved_VBN ._.
        Chemotherapy_NNP has_VBZ become_VBN more_JJR and_CC more_RBR important_JJ and_CC is_VBZ
        considered_VBN to_TO be_VB a_DT major_JJ treatment_NN to_TO avoid_VB the_DT recurrence_NN
        of_IN cancer_NN after_IN surgery_NN [_NN 1_CD ]_NN ._. Although_IN the_DT remission_NN rate_NN
        is_VBZ higher_RBR in_IN previously_RB untreated_JJ patients_NNS ,_, relapse_NN occurs_VBZ
        soon_RB ._. It_PRP has_VBZ been_VBN reported_VBN that_IN most_RBS initially_RB responsive_JJ
        patients_NNS acquire_VB a_DT multidrug_NN resistance_NN (_( MDR_NNP )_) phenotype_NN ._.
        Some_DT other_JJ patients_NNS show_VBP MDR_NNP even_RB in_IN their_PRP$ first_JJ treatment_NN ._.
        In_IN metastatic_JJ breast_NN cancer_NN ,_, the_DT development_NN of_IN a_DT MDR_NNP
        phenotype_NN is_VBZ primarily_RB responsible_JJ for_IN insensitivity_NN to_TO a_DT
        new_JJ drug_NN [_NN 2_CD ]_NN ._.
        Attention_NN has_VBZ been_VBN focused_VBN recently_RB on_IN the_DT study_NN of_IN the_DT
        agents_NNS for_IN reversing_VBG MDR_NNP ._. Although_IN hundreds_NNS of_IN compounds_NNS
        have_VBP been_VBN found_VBN 
        in_IN vitro_NN to_TO be_VB able_JJ to_TO modulate_VBP the_DT
        MDR_NNP phenotype_NN ,_, their_PRP$ clinical_JJ application_NN was_VBD limited_JJ owing_VBG
        to_TO high_JJ toxicity_NN 
        in_IN vivo_NN ._. The_DT key_NN to_TO the_DT clinical_JJ use_NN
        of_IN reversal_NN agents_NNS therefore_RB lies_VBZ in_IN searching_VBG for_IN agents_NNS
        with_IN low_JJ toxicity_NN and_CC high_JJ reversal_NN activity_NN [_NN 3_CD ]_NN ._. In_IN the_DT
        past_JJ ,_, many_JJ progestogen_NN compounds_NNS ,_, such_JJ as_IN MG_NNP and_CC
        medroxyprogesterone_NN ,_, have_VBP been_VBN shown_VBN to_TO have_VB reversal_NN
        effects_NNS 
        in_IN vitro_NN [_NN 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._.
        Unfortunately_RB ,_, the_DT effective_JJ concentration_NN to_TO reverse_VB drug_NN
        resistance_NN 
        in_IN vivo_NN is_VBZ very_RB difficult_JJ to_TO achieve_VB
        [_NN 8_CD ]_NN ._. Nomegestrol_NNP (_( NOM_NNP )_) ,_, a_DT derivative_NN of_IN megestrol_NN (_( MG_NNP )_) ,_,
        has_VBZ very_RB low_JJ toxicity_NN ._. There_EX is_VBZ almost_RB no_DT incidence_NN of_IN
        liver_NN lesions_NNS ,_, pituitory-inhibiting_JJ activity_NN ,_, cortisol-like_JJ
        activity_NN or_CC oestrogen-like_JJ activity_NN ,_, which_WDT are_VBP common_JJ in_IN
        other_JJ progestogen_NN compounds_NNS [_NN 9_CD ]_NN ._. NOM_NNP might_MD therefore_RB be_VB
        suitable_JJ for_IN clinical_JJ use_NN ._.
        In_IN many_JJ previous_JJ studies_NNS on_IN MDR_NNP reversal_NN by_IN compounds_NNS
        related_VBN to_TO NOM_NNP ,_, attention_NN has_VBZ been_VBN paid_VBN to_TO the_DT modulation_NN
        of_IN P-_NNP glycoprotein_NN (_( P-_NNP gp_NN )_) function_NN ._. The_DT reversal_NN mechanism_NN
        consists_VBZ of_IN ,_, for_IN example_NN ,_, binding_JJ directly_RB to_TO P-_NNP gp_NN ,_,
        inhibiting_VBG the_DT transport_NN function_NN of_IN drug_NN efflux_NN ,_,
        increasing_VBG the_DT intracellular_NN accumulation_NN of_IN the_DT drug_NN and_CC
        changing_VBG lipid_NN mobility_NN in_IN the_DT plasma_NN membrane_NN [_NN 4_CD ,_, 10_CD ,_, 11_CD ,_,
        12_CD ]_NN ._. However_RB ,_, different_JJ compounds_NNS have_VBP different_JJ
        mechanisms_NNS ._. No_DT results_NNS on_IN the_DT reversal_NN effect_NN of_IN NOM_NNP or_CC on_IN
        its_PRP$ mechanism_NN were_VBD available_JJ ._. The_DT present_JJ study_NN was_VBD
        directed_VBN to_TO the_DT reversal_NN activity_NN of_IN NOM_NNP on_IN MDR_NNP in_IN
        adriamycin_NN (_( ADR_NNP )_) -_: resistant_JJ (_( MCF_NNP 7_CD /_NN ADR_NNP )_) cells_NNS ,_, and_CC to_TO compare_VB
        NOM_NNP with_IN classic_JJ reversal_NN agents_NNS [_NN verapamil_NN (_( VRP_NNP )_) ,_,
        tamoxifen_NN (_( TAM_NNP )_) ,_, droloxifene_NN (_( DRO_NNP )_) and_CC MG_NNP ]_NN ._. A_DT possible_JJ
        reversal_NN mechanism_NN was_VBD explored_JJ by_IN studying_VBG the_DT cell_NN cycle_NN ,_,
        intracellular_NN drug_NN accumulation_NN and_CC the_DT expression_NN of_IN mRNA_NN
        and_CC proteins_NNS of_IN MDR_NNP 1_CD ,_, glutathione_NN S-_NNP transferase_NN Pi_NNP (_( GSTπ_NNP )_) ,_,
        MDR-related_NNP protein_NN (_( MRP_NNP )_) and_CC topoisomerase_NN IIα_NNP
        (_( TopoIIα_NNP )_) ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cell_NNP line_NN and_CC cell_NN culture_NN
          The_DT cell_NN lines_NNS MCF_NNP 7_CD /_NN WT_NNP (_( ADR-sensitive_NNP )_) and_CC MCF_NNP 7_CD /_NN ADR_NNP
          were_VBD used_VBN in_IN this_DT study_NN ;_: they_PRP were_VBD obtained_VBN from_IN NCI_NNP [_NN
          13_CD ]_NN and_CC maintained_VBN in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN
          incubated_JJ at_IN 37_CD °_NN C_NNP in_IN 5_CD %_NN CO_NNP 
          2_CD -_: 95_CD %_NN air_NN at_IN high_JJ humidity_NN ,_, and_CC
          passaged_JJ every_DT 2_CD -_: 3_CD days_NNS ._. Cells_NNP were_VBD digested_VBN with_IN mixture_NN
          of_IN 0_CD ._. 025_CD %_NN trypsin_NN (_( Gibco_NNP BRL_NNP )_) and_CC 0_CD ._. 01_CD %_NN EDTA_NNP (_( Sigma_NNP )_) ._.
          Medium_NNP for_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS was_VBD further_JJ supplemented_JJ with_IN
          ADR_NNP (_( 10_CD μM_NN ;_: Shanghai_NNP Hualian_NNP Pharmaceutical_NNP Co_NNP ._. Ltd_NNP ._. ,_,
          Shanghai_NNP ,_, China_NNP )_) ._. Before_IN use_NN in_IN experiments_NNS ,_, MCF_NNP 7_CD /_NN ADR_NNP
          cells_NNS were_VBD cultured_JJ in_IN drug-free_JJ medium_NN for_IN 2_CD weeks_NNS ._.
        
        
          The_DT
          3_CD -_: (_( 4_CD ,_, 5_CD -_: dimethylthiazol-_NN 2_CD -_: yl_NN )_) -_: 2_CD ,_, 5_CD -_: diphenyl-_NN 2_CD H-_NNP tetrazolium_NN
          bromide_NN (_( MTT_NNP )_) assay_NN of_IN cytotoxic_JJ activity_NN
          Cells_NNP were_VBD treated_VBN with_IN NOM_NNP (_( purchased_VBN as_IN the_DT acetate_NN
          ester_NN from_IN Pharmaceutical_NNP College_NNP ,_, Shanghai_NNP Medical_NNP
          University_NNP )_) and_CC other_JJ reversal_NN agents_NNS ,_, including_VBG MG_NNP ,_, TAM_NNP ,_,
          DRO_NNP (_( a_DT gift_NN from_IN Professor_NNP Xia_NNP Peng_NNP )_) and_CC VRP_NNP (_( Shanghai_NNP
          Hualian_NNP Pharmaceutical_NNP Co_NNP ._. Ltd_NNP ._. )_) ._. MTT_NNP assays_NNS were_VBD
          performed_VBN as_IN follows_VBZ [_NN 14_CD ]_NN :_: MCF_NNP 7_CD /_NN WT_NNP and_CC MCF_NNP 7_CD /_NN ADR_NNP cells_NNS
          were_VBD each_DT harvested_VBN with_IN 0_CD ._. 05_CD %_NN trypsin_NN /_NN EDTA_NNP and_CC counted_VBN ._.
          Cell_NNP lines_NNS were_VBD seeded_VBN into_IN 96_CD -_: well_RB plates_NNS at_IN 10_CD 4_CD viable_JJ
          cells_NNS per_IN well_RB and_CC left_VBD to_TO attach_VB to_TO the_DT plate_NN for_IN 24_CD h_NN ._.
          After_IN 24_CD h_NN ,_, the_DT medium_NN was_VBD changed_VBN to_TO one_CD containing_VBG or_CC
          lacking_VBG test_NN reversal_NN agents_NNS or_CC ADR_NNP ._. The_DT final_JJ volume_NN was_VBD
          200_CD μl_NN per_IN well_RB ._. The_DT medium_NN was_VBD removed_VBN after_IN 72_CD h_NN of_IN
          incubation_NN ._. Other_JJ medium_NN containing_VBG 0_CD ._. 5_CD mg_NN /_NN ml_NN MTT_NNP (_( Sigma_NNP )_)
          was_VBD added_VBN to_TO each_DT well_RB in_IN a_DT volume_NN of_IN 200_CD μl_NN and_CC
          incubated_JJ for_IN 4_CD h_NN ._. The_DT medium_NN was_VBD then_RB removed_VBN and_CC 180_CD μl_NN
          of_IN dimethyl_NN sulphoxide_NN (_( Sigma_NNP )_) was_VBD added_VBN to_TO each_DT well_RB for_IN
          half_PDT an_DT hour_NN at_IN room_NN temperature_NN ._. A_DT 96_CD -_: well_RB microtitre_NN
          plate_NN reader_NN (_( Dynatech_NNP ,_, Chantilly_NNP ,_, VA_NNP ,_, USA_NNP )_) was_VBD used_VBN to_TO
          determine_VB 
          A_DT 
          570_CD ._. The_DT mean_JJ concentration_NN in_IN each_DT
          set_NN of_IN three_CD wells_NNS was_VBD measured_VBN ._. To_TO avoid_VB interference_NN by_IN
          the_DT red_JJ fluorescence_NN of_IN ADR_NNP concentrations_NNS above_IN 8_CD μM_NN ,_, a_DT
          blank_NN well_RB containing_VBG the_DT corresponding_JJ ADR_NNP concentration_NN
          without_IN MTT_NNP was_VBD set_VBN up_RP and_CC subtracted_VBN from_IN the_DT test_NN well_RB
          absorbance_NN ._. The_DT absorbance_NN of_IN untreated_JJ controls_NNS was_VBD
          taken_VBN as_IN 100_CD %_NN survival_NN ,_, and_CC the_DT percentage_NN inhibition_NN was_VBD
          calculated_VBN as_IN cell_NN survival_NN rate_NN (_( %_NN )_) =_SYM 100_CD (_( 
          T_NN -_: 
          B_NNP )_) /_NN (_( 
          U_NNP -_: 
          B_NNP )_) ,_, and_CC growth_NN inhibition_NN (_( %_NN )_) =_SYM
          100_CD -_: cell_NN survival_NN rate_NN (_( %_NN )_) ,_, where_WRB 
          T_NN (_( treated_VBN )_) is_VBZ the_DT absorbance_NN of_IN
          drug-treated_JJ cells_NNS ,_, 
          U_NNP (_( untreated_JJ )_) is_VBZ the_DT absorbance_NN of_IN
          untreated_JJ cells_NNS and_CC 
          B_NNP (_( blank_JJ )_) is_VBZ the_DT absorbance_NN in_IN the_DT
          absence_NN of_IN both_DT drug_NN and_CC MTT_NNP ._.
          IC_NNP 
          50_CD values_NNS were_VBD determined_VBN graphically_RB
          from_IN relative_JJ survival_NN curves_NNS ._.
          The_DT fold_VB reversal_NN was_VBD calculated_VBN as_IN IC_NNP 
          50_CD for_IN ADR_NNP /_NN IC_NNP 
          50_CD for_IN ADR_NNP plus_CC reversal_NN agents_NNS ._.
        
        
          Semiquantitative_NNP reverse_VB transcriptase_NN polymerase_NN
          chain_NN reaction_NN (_( RT-PCR_NNP )_) analysis_NN
          
            NOM_NNP treatment_NN
            Cells_NNP were_VBD subjected_VBN to_TO mild_JJ treatment_NN with_IN trypsin_NN
            and_CC plated_JJ at_IN a_DT density_NN of_IN 10_CD 5_CD cells_NNS /_NN ml_NN ._. NOM_NNP was_VBD tested_VBN
            at_IN 5_CD μM_NN ;_: cells_NNS were_VBD passaged_JJ as_IN usual_JJ ._. After_IN 2_CD ,_, 3_CD ,_, 5_CD
            and_CC 10_CD days_NNS ,_, NOM-containing_NNP medium_NN was_VBD removed_VBN and_CC
            cells_NNS were_VBD harvested_VBN ._.
          
          
            RNA_NNP isolation_NN
            Total_NNP RNA_NNP was_VBD extracted_VBN from_IN the_DT treated_VBN cell_NN line_NN
            or_CC control_NN samples_NNS with_IN the_DT TRIzol_NNP system_NN (_( Gibco_NNP BRL_NNP )_) ,_,
            in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS instructions_NNS ._. The_DT
            concentration_NN and_CC purity_NN of_IN RNA_NNP were_VBD quantified_VBN
            spectrophotometrically_RB by_IN measuring_VBG 
            A_DT 
            260_CD and_CC 
            A_DT 
            280_CD ;_: the_DT ratio_NN 
            A_DT 
            260_CD /_NN 
            A_DT 
            280_CD of_IN pure_JJ RNA_NNP is_VBZ approximately_RB
            1_CD ._. 8_CD ._. The_DT sample_NN was_VBD stored_VBN at_IN -_: 70_CD °_NN C_NNP ._.
          
          
            Reverse_VBP transcription_NN reaction_NN
            The_DT RNA_NNP sample_NN was_VBD added_VBN to_TO a_DT sterile_JJ RNase-free_NNP
            micro-centrifuge_JJ tube_NN ,_, and_CC nuclease-free_JJ water_NN was_VBD
            added_VBN to_TO 9_CD ._. 5_CD μl_NN ._. The_DT RNA_NNP sample_NN was_VBD heated_VBN to_TO 70_CD °_NN C_NNP for_IN
            10_CD min_NN ,_, then_RB chilled_VBN on_IN ice_NN ._. To_TO this_DT ,_, 4_CD μl_NN of_IN a_DT 5_CD ×_NN AMV_NNP
            RT_NNP reaction_NN buffer_NN ,_, 2_CD μl_NN of_IN 25_CD mM_NN MgCl_NNP ,_, 2_CD μl_NN of_IN 10_CD mM_NN
            dNTP_NN ,_, 0_CD ._. 5_CD μl_NN of_IN Rnasin_NNP (_( 1_CD U_NNP /_NN μl_NN )_) (_( Promega_NNP )_) ,_, 1_CD μl_NN of_IN
            oligo_NN (_( dT_NN )_) 
            15_CD (_( 0_CD ._. 5_LS μg_NN /_NN μl_NN )_) (_( Promega_NNP )_) and_CC 1_CD μl_NN of_IN
            AMV_NNP RT_NNP (_( 10_CD U_NNP /_NN μl_NN )_) (_( Promega_NNP )_) were_VBD added_VBN ._. The_DT final_JJ volume_NN
            was_VBD 20_CD μl_NN ._. This_DT mixture_NN was_VBD centrifuged_JJ shortly_RB ,_, then_RB
            incubated_JJ at_IN 42_CD °_NN C_NNP for_IN 1_CD h_NN to_TO allow_VB the_DT AMV_NNP RT_NNP enzyme_NN to_TO
            catalyse_NN the_DT formation_NN of_IN cDNA_NN on_IN the_DT mRNA_NN template_NN ._.
            The_DT enzyme_NN was_VBD then_RB inactivited_JJ by_IN being_VBG heated_VBN to_TO 95_CD °_NN C_NNP
            for_IN 2_CD min_NN ._. The_DT cDNA_NN was_VBD stored_VBN at_IN -_: 20_CD °_NN C_NNP until_IN required_VBN
            for_IN analysis_NN ._.
          
          
            PCR_NNP
            PCR_NNP was_VBD set_VBN up_RP as_IN described_VBN previously_RB [_NN 15_CD ]_NN ._. Two_CD
            sets_NNS of_IN primers_NNS were_VBD used_VBN in_IN all_DT reactions_NNS to_TO yield_VB the_DT
            amplification_NN of_IN an_DT endogenous_JJ control_NN gene_NN (_( β-actin_JJ ,_,
            383_CD bases_NNS )_) and_CC the_DT specific_JJ target_NN genes_NNS of_IN interest_NN
            [_NN 157_CD bases_NNS of_IN MDR_NNP 1_CD (_( a_DT gift_NN from_IN Jian_NNP Lin_NNP ,_, Cancer_NNP
            Center_NNP /_NN Institute_NNP of_IN Cancer_NNP Research_NNP ,_, Golumbia_NNP
            University_NNP ,_, College_NNP of_IN Physicians_NNPS and_CC Surgeons_NNP ,_, New_NNP
            York_NNP ,_, USA_NNP )_) ,_, 270_CD bases_NNS of_IN GSTπ_NNP ,_, 203_CD bases_NNS of_IN MRP_NNP and_CC 139_CD
            bases_NNS of_IN TopoIIα_NNP independently_RB (_( Table_NNP 1_LS )_) [_NN 15_CD ]_NN ]_NN ._. PCR_NNP
            amplification_NN was_VBD performed_VBN on_IN 1_CD μl_NN of_IN RT_NNP product_NN (_( 25_CD
            μM_NN )_) incubated_JJ with_IN 0_CD ._. 5_CD U_NNP of_IN 
            Taq_NNP DNA_NNP polymease_NN (_( Promega_NNP )_) in_IN a_DT
            25_CD μl_NN reaction_NN mixture_NN containing_VBG 0_CD ._. 5_CD μM_NN 10_CD mM_NN dNTP_NN ,_,
            1_CD ._. 5_CD μl_NN of_IN 25_CD mM_NN MgCl_NNP ,_, 2_CD ._. 5_CD μl_NN of_IN 10_CD ×_NN 
            Taq_NNP DNA_NNP polymerase_NN buffer_NN from_IN
            Promega_NNP ,_, 10_CD pmol_NN of_IN internal_JJ standard_JJ gene_NN upstream_RB and_CC
            downstream_JJ primers_NNS to_TO minimize_VB variations_NNS in_IN
            amplification_NN efficiency_NN between_IN tubes_NNS ._.
            PCR_NNP was_VBD performed_VBN with_IN the_DT use_NN of_IN Gene_NNP Amp_NNP PCR_NNP
            Systems_NNPS 9700_CD (_( Perkin_NNP Elmer_NNP ,_, Watsonville_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. For_IN
            MDR_NNP 1_CD ,_, GSTπ_NNP and_CC TopoIIα_NNP genes_NNS ,_, after_IN an_DT initial_JJ
            denaturation_NN at_IN 94_CD °_NN C_NNP for_IN 1_CD ._. 5_CD min_NN ,_, 30_CD cycles_NNS of_IN PCR_NNP
            amplification_NN were_VBD performed_VBN ,_, each_DT cycle_NN consisting_VBG of_IN
            a_DT denaturing_VBG step_NN of_IN 94_CD °_NN C_NNP for_IN 1_CD ._. 5_CD min_NN ,_, annealing_VBG at_IN
            54_CD °_NN C_NNP for_IN 1_CD min_NN ,_, and_CC extension_NN at_IN 72_CD °_NN C_NNP for_IN 3_CD min_NN ,_,
            followed_VBN by_IN a_DT final_JJ step_NN at_IN 72_CD °_NN C_NNP for_IN 10_CD min_NN ._. For_IN the_DT
            MRP_NNP gene_NN ,_, after_IN an_DT initial_JJ denaturation_NN step_NN of_IN 95_CD °_NN C_NNP
            for_IN 4_CD min_NN ,_, 35_CD cycles_NNS of_IN PCR_NNP amplification_NN were_VBD
            performed_VBN ,_, each_DT cycle_NN consisting_VBG of_IN a_DT denaturing_VBG step_NN
            of_IN 95_CD °_NN C_NNP for_IN 25_CD s_VBZ ,_, annealing_VBG at_IN 54_CD °_NN C_NNP for_IN 30_CD s_VBZ ,_, and_CC
            extension_NN at_IN 73_CD °_NN C_NNP for_IN 60_CD s_VBZ ,_, followed_VBN by_IN a_DT final_JJ step_NN at_IN
            72_CD °_NN C_NNP for_IN 8_CD min_NN ._. The_DT amplified_VBN fragments_NNS were_VBD detected_VBN
            by_IN 2_CD %_NN (_( w_NN /_NN v_NN )_) agarose_NN gel_NN electrophoresis_NNS and_CC staining_VBG
            with_IN 0_CD ._. 3_CD μg_NN /_NN ml_NN ethidium_NN bromide_NN (_( Sigma_NNP )_) ._. Each_DT band_NN was_VBD
            analysed_JJ on_IN image_NN analysis_NN system_NN IS_VBZ 1000_CD (_( Alpha_NNP
            Innotech_NNP ,_, San_NNP Leandro_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. The_DT specific_JJ gene_NN
            expression_NN level_NN was_VBD determined_VBN semiquantitatively_RB by_IN
            calculating_VBG the_DT ratio_NN of_IN density_NN metric_JJ value_NN from_IN
            specific_JJ genes_NNS expressed_VBD in_IN relation_NN to_TO the_DT internal_JJ
            standard_JJ (_( specific_JJ gene_NN expression_NN /_NN β-actin_JJ
            expression_NN )_) ._.
          
        
        
          Immunocytochemistry_NNP staining_VBG
          Treatment_NNP with_IN 5_CD μM_NN NOM_NNP was_VBD performed_VBN as_IN above_IN (_( see_VB
          RT-PCR_NNP )_) ._. A_DT smear_NN was_VBD made_VBN from_IN each_DT cell_NN sample_NN ;_: after_IN
          the_DT smear_NN had_VBD dried_VBN in_IN air_NN ,_, cells_NNS were_VBD fixed_VBN in_IN acetone_NN
          for_IN 10_CD min_NN ._. Immunocytochemistry_NNP was_VBD performed_VBN with_IN an_DT
          avidin-biotin_JJ complex_JJ immunoperoxidase_NN method_NN as_IN
          described_VBN by_IN Zhou_NNP [_NN 16_CD ]_NN ,_, with_IN some_DT modifications_NNS ._.
          Monoclonal_NNP antibody_NN against_IN P-_NNP gp_NN (_( JSB-_NNP 1_LS )_) was_VBD purchased_VBN
          from_IN Boehringer_NNP Mannheim_NNP Biochemica_NNP ;_: monoclonal_NN
          antibodies_NNS against_IN GSTπ_NNP and_CC TopoIIα_NNP were_VBD purchased_VBN from_IN
          Dako_NNP Corporation_NNP and_CC Neomarker_NNP ,_, respectively_RB ._. In_IN brief_JJ ,_,
          after_IN three_CD washes_NNS with_IN phosphate-buffered_JJ saline_NN (_( PBS_NNP )_) ,_,
          fixed_VBN cells_NNS in_IN each_DT smear_NN were_VBD layered_JJ with_IN the_DT primary_JJ
          antibody_NN against_IN P-_NNP gp_NN (_( 1_CD :_: 20_CD dilution_NN )_) ,_, GSTπ_NNP (_( 1_CD :_: 25_CD
          dilution_NN )_) and_CC TopoIIα_NNP (_( 1_CD :_: 50_CD dilution_NN )_) and_CC incubated_JJ
          overnight_JJ (_( a_DT minimum_NN of_IN 18_CD h_NN )_) ._. After_IN three_CD washes_NNS with_IN
          PBS_NNP ,_, the_DT cells_NNS were_VBD incubated_JJ with_IN secondary_JJ antibody_NN
          mixture_NN of_IN anti-mouse_JJ Ig_NNP (_( 1_CD :_: 200_CD dilution_NN ;_: Huamei_NNP BG_NNP Co_NNP
          Ltd_NNP ,_, Shanghai_NNP ,_, China_NNP )_) for_IN 2_CD h_NN at_IN room_NN temperature_NN ._. The_DT
          cells_NNS were_VBD washed_VBN as_IN before_IN and_CC then_RB incubated_JJ with_IN ABC_NNP
          complex_JJ (_( 1_CD :_: 100_CD dilution_NN ;_: Huamei_NNP BG_NNP Co_NNP Ltd_NNP )_) for_IN 1_CD h_NN at_IN
          room_NN temperature_NN ._. After_IN being_VBG washed_VBN ,_, cells_NNS were_VBD
          developed_VBN in_IN 0_CD ._. 04_CD %_NN 3_CD ,_, 3_CD -_: diaminobenzidine_NN
          tetrahydrochloride_NN dihydrate_NN (_( Sigma_NNP )_) with_IN 0_CD ._. 02_CD %_NN H_NNP 
          2_CD O_NNP 
          2_CD in_IN PBS_NNP for_IN 15_CD -_: 30_CD min_NN ._. Cells_NNP were_VBD
          washed_VBN again_RB with_IN PBS_NNP and_CC counterstained_JJ with_IN
          haematoxylin_NN ._.
          In_IN each_DT assay_NN ,_, five_CD categories_NNS of_IN staining_VBG were_VBD
          observed_VBN as_IN defined_VBN previously_RB [_NN 17_CD ]_NN ._. In_IN brief_JJ ,_, we_PRP first_RB
          determined_VBD the_DT staining_VBG grade_NN I_PRP :_: 0_CD ,_, no_DT staining_VBG ;_: 1_CD ,_, pale_JJ
          yellow_NN ;_: 2_CD ,_, brown_JJ yellow_NN ;_: 3_CD ,_, brownish_NN ._. Then_RB we_PRP calculated_VBD
          the_DT grade_NN II_NNP according_VBG to_TO the_DT ratio_NN of_IN positive_JJ staining_VBG
          cells_NNS to_TO total_VB tumour_NN cells_NNS :_: 0_CD ,_, no_DT staining_VBG ;_: 1_CD ,_, less_JJR than_IN
          10_CD %_NN ;_: 2_CD ,_, 11_CD -_: 50_CD %_NN ;_: 3_CD ,_, 51_CD -_: 75_CD %_NN ;_: 4_CD ,_, more_JJR than_IN 75_CD %_NN ._. Finally_RB ,_,
          according_VBG to_TO total_VB grade_NN (_( total_JJ grade_NN =_SYM grade_NN I_PRP ×_NN grade_NN
          II_NNP )_) ,_, the_DT immunocytochemistry_NN assay_NN standard_NN was_VBD
          determined_VBN as_IN follows_VBZ :_: total_JJ grade_NN 0_CD ,_, negative_JJ ;_: 1_CD -_: 3_CD ,_,
          feeble_JJ positive_NN ;_: 4_CD or_CC 5_CD ,_, weak_JJ positive_NN ;_: 6_CD or_CC 7_CD ,_, moderate_JJ
          positive_NN ;_: more_JJR than_IN 7_CD ,_, strong_JJ positive_NN ._.
        
        
          ADR_NNP accumulation_NN
          Accumulation_NNP of_IN ADR_NNP was_VBD monitored_VBN using_VBG a_DT standard_JJ
          procedure_NN by_IN incubating_VBG MCF_NNP 7_CD /_NN ADR_NNP cells_NNS (_( 5_CD ×_NN 10_CD 5_CD /_NN ml_NN )_) for_IN
          2_CD h_NN at_IN 37_CD °_NN C_NNP in_IN the_DT presence_NN of_IN ADR_NNP (_( 10_CD μM_NN )_) alone_RB or_CC in_IN
          combination_NN with_IN NOM_NNP (_( 20_CD ,_, 10_CD or_CC 5_CD μM_NN )_) ._. Cells_NNP were_VBD then_RB
          harvested_VBN and_CC washed_VBN twice_RB with_IN cold_JJ (_( 0_CD °_NN C_NNP )_) PBS_NNP ,_, then_RB
          placed_VBN in_IN ice-water_JJ to_TO block_VB the_DT reaction_NN until_IN analysis_NN ._.
          After_IN half_PDT an_DT hour_NN ,_, the_DT fluorescence_NN intensity_NN of_IN cells_NNS
          (_( 10_CD 4_CD /_NN ml_NN )_) was_VBD determined_VBN by_IN flow_NN cytometry_NN (_( FCM_NNP )_)
          (_( FAC-SCalibar_NNP ;_: Becton_NNP Dickinson_NNP ,_, San_NNP Jose_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Cell_NNP cycle_NN analysis_NN
          Cells_NNP were_VBD plated_JJ at_IN 2_CD ×_NN 10_CD 5_CD /_NN ml_NN in_IN specific_JJ medium_NN
          supplemented_JJ as_IN above_IN ._. After_IN 24_CD h_NN the_DT medium_NN was_VBD replaced_VBN
          with_IN fresh_JJ medium_NN containing_VBG ADR_NNP alone_RB or_CC in_IN combination_NN
          with_IN NOM_NNP (_( 20_CD μM_NN )_) ._. The_DT cells_NNS were_VBD harvested_VBN after_IN 48_CD h_NN and_CC
          washed_VBN twice_RB with_IN PBS_NNP ,_, then_RB fixed_VBN with_IN 70_CD %_NN (_( v_NN /_NN v_NN )_) ethanol_NN ._.
          The_DT sample_NN was_VBD concentrated_VBN by_IN removing_VBG ethanol_NN and_CC
          treated_VBN with_IN 1_CD %_NN (_( v_NN /_NN v_NN )_) Triton_NNP X-_NNP 100_CD and_CC 0_CD ._. 01_CD %_NN RNase_NNP for_IN 10_CD
          min_NN ._. Staining_NNP of_IN cellular_JJ DNA_NNP was_VBD performed_VBN with_IN 0_CD ._. 05_CD %_NN
          propidium_NN iodide_NN for_IN 20_CD min_NN at_IN 4_CD °_NN C_NNP ._. FCM_NNP analysis_NN was_VBD
          performed_VBN by_IN acquiring_VBG a_DT minimum_NN of_IN 2_CD ×_NN 10_CD 5_CD nuclei_NN ._. Cell_NNP
          cycle_NN analysis_NN was_VBD performed_VBN with_IN the_DT MultiCycle_NNP software_NN
          package_NN (_( Phoenix_NNP ,_, San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Statistical_NNP analysis_NN
          Levels_NNP of_IN statistical_JJ significance_NN were_VBD evaluated_VBN with_IN
          data_NNS from_IN at_IN least_JJS three_CD independent_JJ experiments_NNS by_IN using_VBG
          Student_NNP 's_POS 
          t_NN test_NN ._. 
          P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._.
        
      
      
        Results_NNS
        
          Enhancement_NNP of_IN chemosensitivity_NN in_IN treated_VBN
          cells_NNS
          Cytotoxicity_NNP was_VBD expressed_VBN as_IN the_DT percentage_NN growth_NN
          inhibition_NN compared_VBN with_IN untreated_JJ control_NN cells_NNS ._. MTT_NNP
          assays_NNS showed_VBD that_IN 1_CD ._. 5_CD %_NN ethanol_NN or_CC 20_CD μM_NN NOM_NNP and_CC other_JJ
          various_JJ reversal_NN agents_NNS showed_VBD no_DT toxicity_NN towards_IN the_DT
          two_CD cell_NN lines_NNS ._. In_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS treated_VBN with_IN NOM_NNP (_( 5_CD μM_NN )_)
          for_IN 10_CD days_NNS the_DT cell_NN growth_NN rate_NN was_VBD normal_JJ compared_VBN with_IN
          control_NN cells_NNS ,_, as_IN judged_VBN by_IN staining_VBG with_IN trypan_NN blue_JJ ._.
          The_DT results_NNS showed_VBD that_IN 20_CD ,_, 10_CD and_CC 5_CD μM_NN NOM_NNP significantly_RB
          increased_VBD the_DT sensitivity_NN of_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS to_TO ADR_NNP ,_, the_DT
          degrees_NNS of_IN reversal_NN being_VBG 21_CD -_: fold_VB ,_, 12_CD -_: fold_VB and_CC 8_CD -_: fold_VB ,_,
          respectively_RB (_( Fig_NNP ._. 1_LS b_SYM )_) ._. The_DT reversal_NN activity_NN of_IN 20_CD ,_, 10_CD
          and_CC 5_CD μM_NN NOM_NNP was_VBD markedly_RB stronger_JJR than_IN that_DT of_IN the_DT same_JJ
          concentration_NN of_IN DRO_NNP and_CC MG_NNP (_( Fig_NNP ._. 2_LS )_) and_CC was_VBD similar_JJ to_TO
          that_DT of_IN the_DT classic_JJ agents_NNS VRP_NNP and_CC TAM_NNP ._. In_IN MCF_NNP 7_CD /_NN WT_NNP cells_NNS
          neither_DT NOM_NNP nor_CC other_JJ reversal_NN compounds_NNS increased_VBD
          chemosensitivity_NN to_TO ADR_NNP (_( Table_NNP 2_LS )_) ._.
        
        
          MDR-related_NNP gene_NN expression_NN in_IN NOM-treated_NNP
          cells_NNS
          
            MDR_NNP 1_CD and_CC GSTπ_NNP mRNA_NN expression_NN
            After_IN treatment_NN with_IN 5_CD μM_NN NOM_NNP ,_, the_DT MDR_NNP 1_CD and_CC GSTπ_NNP
            expression_NN levels_NNS of_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS were_VBD modulated_JJ in_IN a_DT
            time-dependent_JJ manner_NN ._. The_DT expression_NN of_IN both_DT mRNA_NN
            species_NNS began_VBD to_TO decrease_VB on_IN the_DT second_JJ day_NN (_( 
            P_NN <_NN 0_CD ._. 05_CD and_CC 
            P_NN <_NN 0_CD ._. 01_CD ,_, respectively_RB )_) ,_, and_CC
            reached_VBD the_DT lowest_JJS level_NN on_IN the_DT third_JJ day_NN (_( both_DT 
            P_NN <_NN 0_CD ._. 01_CD )_) ._. The_DT expression_NN
            level_NN began_VBD to_TO rise_VB as_IN detected_VBN on_IN the_DT fifth_JJ day_NN (_( 
            P_NN >_NN 0_CD ._. 05_CD and_CC 
            P_NN <_NN 0_CD ._. 05_CD ,_, respectively_RB )_) ,_, and_CC
            reached_VBD a_DT level_NN close_RB to_TO that_DT of_IN untreated_JJ controls_NNS on_IN
            the_DT tenth_NN day_NN (_( Fig_NNP ._. 3_LS ,_, Table_NNP 3_LS )_) ._.
          
          
            MRP_NNP and_CC TopoIIα_NNP mRNA_NN expression_NN
            After_IN treatment_NN with_IN NOM_NNP ,_, the_DT MRP_NNP mRNA_NN expression_NN
            level_NN of_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS tended_VBD to_TO decrease_VB on_IN the_DT
            second_JJ day_NN ,_, with_IN no_DT statistical_JJ significance_NN ._. No_DT
            significant_JJ change_NN was_VBD found_VBN in_IN TopoIIα_NNP expression_NN
            level_NN when_WRB measured_VBN on_IN the_DT second_JJ ,_, third_JJ ,_, fifth_NN and_CC
            tenth_NN days_NNS after_IN treatment_NN in_IN comparison_NN with_IN the_DT
            control_NN ._. No_DT significant_JJ changes_NNS in_IN MRP_NNP and_CC TopoIIα_NNP mRNA_NN
            expression_NN levels_NNS were_VBD found_VBN in_IN MCF_NNP 7_CD /_NN WT_NNP cells_NNS (_( Table_NNP
            3_LS )_) ._.
          
        
        
          Expression_NNP of_IN P-_NNP gp_NN ,_, GSTπ_NNP and_CC TopoIIα_NNP
          proteins_NNS
          MCF_NNP 7_CD /_NN ADR_NNP cells_NNS had_VBD high_JJ expression_NN levels_NNS of_IN P-_NNP gp_NN and_CC
          GSTπ_NNP proteins_NNS and_CC a_DT moderate_JJ expression_NN level_NN of_IN TopoIIα_NNP
          protein_NN ._. MCF_NNP 7_CD /_NN WT_NNP cells_NNS expressed_VBD a_DT high_JJ level_NN of_IN TopoIIα_NNP
          only_RB :_: P-_NNP gp_NN and_CC GSTπ_NNP protein_NN expression_NN were_VBD undetectable_JJ ._.
          After_IN treatment_NN with_IN NOM_NNP ,_, the_DT expression_NN levels_NNS of_IN P-_NNP gp_NN
          and_CC GSTπ_NNP in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS gradually_RB declined_VBD ,_, the_DT lowest_JJS
          level_NN being_VBG on_IN the_DT third_JJ day_NN ;_: on_IN the_DT fifth_JJ day_NN their_PRP$
          expression_NN levels_NNS began_VBD to_TO rise_VB ._. No_DT marked_VBN difference_NN
          whose_WP$ TopoIIα_NNP protein_NN expression_NN was_VBD found_VBN before_IN and_CC
          after_IN NOM_NNP treatment_NN in_IN either_DT MCF_NNP 7_CD /_NN ADR_NNP or_CC MCF_NNP 7_CD /_NN WT_NNP cells_NNS ._.
          The_DT effects_NNS of_IN NOM_NNP on_IN the_DT expression_NN of_IN drug_NN resistance_NN
          protein_NN were_VBD similar_JJ to_TO those_DT of_IN NOM_NNP on_IN mRNA_NN expression_NN
          (_( Figs_NNP 4_CD and_CC 5_LS )_) ._.
        
        
          ADR_NNP accumulation_NN and_CC cell_NN cycle_NN changes_NNS in_IN
          NOM-treated_NNP cells_NNS
          The_DT accumulation_NN of_IN ADR_NNP in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS was_VBD much_RB
          less_JJR than_IN in_IN MCF_NNP 7_CD /_NN WT_NNP cells_NNS ._. Each_DT cell_NN line_NN was_VBD treated_VBN
          with_IN 20_CD ,_, 10_CD and_CC 5_CD μM_NN NOM_NNP ._. Marked_NNP increases_NNS in_IN
          intracellular_NN ADR_NNP accumulation_NN were_VBD found_VBN in_IN MCF_NNP 7_CD /_NN ADR_NNP
          cells_NNS ,_, the_DT increases_NNS being_VBG 2_CD ._. 7_CD -_: fold_VB ,_, 2_CD ._. 3_CD -_: fold_VB and_CC
          1_CD ._. 5_CD -_: fold_VB ,_, respectively_RB ._. However_RB ,_, NOM_NNP did_VBD not_RB increase_VB ADR_NNP
          accumulation_NN in_IN MCF_NNP 7_CD /_NN WT_NNP cells_NNS (_( Fig_NNP ._. 6_CD )_) ._. FCM_NNP analysis_NN was_VBD
          performed_VBN in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS treated_VBN for_IN 48_CD h_NN with_IN ADR_NNP
          alone_RB or_CC in_IN combination_NN with_IN 20_CD μM_NN NOM_NNP ._. The_DT results_NNS
          showed_VBD that_IN when_WRB the_DT ADR_NNP concentration_NN was_VBD increased_VBN from_IN
          5_CD μM_NN to_TO 40_CD μM_NN ,_, only_RB a_DT small_JJ increase_NN in_IN arrested_VBN cells_NNS at_IN
          the_DT G_NNP 
          2_CD M_NNP phase_NN was_VBD found_VBN in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS
          treated_VBN with_IN ADR_NNP alone_RB ._. However_RB ,_, when_WRB ADR_NNP was_VBD used_VBN in_IN
          combination_NN with_IN 20_CD μM_NN NOM_NNP ,_, a_DT marked_VBN arrest_NN was_VBD seen_VBN ._. NOM_NNP
          alone_RB failed_VBD to_TO induce_VB any_DT change_NN in_IN the_DT cell_NN cycle_NN (_( Fig_NNP ._.
          7_CD and_CC Table_NNP 4_LS )_) ._.
        
      
      
        Discussion_NNP
        The_DT overexpression_NN of_IN P-_NNP gp_NN in_IN tumour_NN cell_NN membrane_NN is_VBZ
        considered_VBN to_TO be_VB the_DT major_JJ mechanism_NN of_IN MDR_NNP ._. P-_NNP gp_NN is_VBZ able_JJ
        to_TO pump_VB various_JJ anticancer_NN drugs_NNS out_IN of_IN cells_NNS ,_, thus_RB
        resulting_VBG in_IN a_DT low_JJ intracellular_NN drug_NN concentration_NN that_WDT is_VBZ
        insufficient_JJ to_TO kill_VB tumour_NN cells_NNS [_NN 18_CD ]_NN ._. To_TO use_VB compounds_NNS
        with_IN low_JJ toxicity_NN ,_, or_CC with_IN none_NN at_IN all_DT ,_, to_TO bind_NN P-_NNP gp_NN and_CC
        block_VB its_PRP$ transport_NN function_NN is_VBZ the_DT most_RBS common_JJ method_NN of_IN
        reversing_VBG MDR_NNP [_NN 19_CD ]_NN ._. Progesterone_NNP and_CC MG_NNP belong_VBP to_TO the_DT
        progestogen_NN group_NN ._. Although_IN progesterone_NN is_VBZ not_RB a_DT substrate_NN
        for_IN P-_NNP gp_NN ,_, it_PRP can_MD directly_RB bind_NN to_TO P-_NNP gp_NN and_CC block_VB the_DT
        transport_NN of_IN drug_NN efflux_NN [_NN 20_CD ]_NN ._. MG_NNP is_VBZ a_DT strong_JJ reversal_NN
        agent_NN :_: its_PRP$ capacity_NN to_TO increase_VB intracellular_NN accumulation_NN
        of_IN vincristine_NN is_VBZ 2_CD -_: 3_CD -_: fold_VB that_IN of_IN progesterone_NN [_NN 6_CD ]_NN ._.
        Previous_JJ results_NNS have_VBP shown_VBN that_IN a_DT daily_JJ dose_NN of_IN 800_CD mg_NN MG_NNP
        resulted_VBD in_IN a_DT plasma_NN concentration_NN of_IN 2_CD μM_NN [_NN 21_CD ]_NN ;_: however_RB ,_,
        to_TO reverse_VB MDR_NNP ,_, 5_CD μM_NN is_VBZ necessary_JJ in_IN theory_NN ._. Because_IN high_JJ
        doses_NNS of_IN MG_NNP induce_VB vomiting_NN ,_, oedema_NN ,_, dizziness_NN and_CC
        androgen-like_JJ side-effects_JJ ,_, the_DT ideal_JJ effective_JJ
        concentration_NN is_VBZ difficult_JJ to_TO obtain_VB 
        in_IN vivo_NN ._. Therefore_RB ,_, the_DT search_NN for_IN
        new_JJ drugs_NNS with_IN low_JJ toxicity_NN is_VBZ in_IN progress_NN to_TO meet_VB an_DT
        urgent_JJ need_NN for_IN clinical_JJ applications_NNS ._.
        NOM_NNP is_VBZ a_DT progestogen_NN compound_NN used_VBN in_IN family_NN planning_NN ._.
        In_IN recent_JJ years_NNS ,_, biological_JJ activities_NNS other_JJ than_IN
        contraception_NN have_VBP been_VBN found_VBN [_NN 22_CD ]_NN ._. Animal_NNP experiments_NNS
        have_VBP demonstrated_VBN that_IN NOM_NNP has_VBZ almost_RB no_DT toxicity_NN ._. Its_PRP$ full_JJ
        chemical_NN name_NN is_VBZ
        3_CD ,_, 20_CD -_: diketo-_NN 6_CD -_: methyl-_NN 17_CD -_: α-hydroxy-_JJ 19_CD -_: norpregna-_NN 4_CD ,_, 6_CD -_: diene_NN [_NN
        9_CD ]_NN ._.
        The_DT present_JJ study_NN has_VBZ demonstrated_VBN that_IN NOM_NNP
        significantly_RB sensitizes_NNS the_DT MCF_NNP 7_CD /_NN ADR_NNP cell_NN line_NN to_TO ADR_NNP in_IN a_DT
        concentration-dependent_JJ manner_NN ,_, but_CC has_VBZ no_DT similar_JJ effect_NN
        on_IN MCF_NNP 7_CD /_NN WT_NNP cells_NNS ._. The_DT reversal_NN effects_NNS of_IN 20_CD ,_, 10_CD and_CC 5_CD μM_NN
        NOM_NNP were_VBD 21_CD -_: fold_VB ,_, 12_CD -_: fold_VB and_CC 8_CD -_: fold_VB ,_, respectively_RB ._. The_DT
        enhancement_NN of_IN chemosensitivity_NN to_TO ADR_NNP by_IN NOM_NNP was_VBD stronger_JJR
        than_IN that_DT by_IN MG_NNP ,_, a_DT precursor_NN of_IN NOM_NNP ,_, at_IN corresponding_JJ
        concentrations_NNS (_( 
        P_NN <_NN 0_CD ._. 05_CD )_) ._. The_DT reversal_NN effect_NN of_IN
        NOM_NNP was_VBD similar_JJ to_TO that_DT of_IN VRP_NNP ,_, which_WDT is_VBZ a_DT classical_JJ
        reversal_NN agent_NN with_IN a_DT high_JJ reversal_NN activity_NN ;_: NOM_NNP therefore_RB
        also_RB has_VBZ a_DT strong_JJ reversal_NN activity_NN ._.
        Both_DT TAM_NNP and_CC DRO_NNP are_VBP anti-oestrogen_JJ agents_NNS ._. TAM_NNP is_VBZ a_DT
        first-line_JJ drug_NN used_VBN in_IN endocrinotherapy_NN for_IN breast_NN cancer_NN ._.
        Anti-oestrogens_NNP can_MD inhibit_VB P-_NNP gp_NN function_NN by_IN binding_JJ it_PRP [_NN
        23_CD ]_NN ._. In_IN our_PRP$ study_NN ,_, the_DT effect_NN of_IN NOM_NNP was_VBD significantly_RB
        greater_JJR than_IN that_DT of_IN DRO_NNP ._.
        The_DT development_NN of_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS was_VBD induced_VBN by_IN
        treating_VBG MCF_NNP 7_CD /_NN WT_NNP with_IN ADR_NNP ._. Its_PRP$ MDR_NNP phenotype_NN is_VBZ not_RB altered_VBN
        after_IN 3_CD months_NNS of_IN serial_NN passaging_VBG in_IN drug-free_JJ medium_NN [_NN
        24_CD ,_, 25_CD ]_NN ._. MCF_NNP 7_CD /_NN ADR_NNP cells_NNS have_VBP been_VBN demonstrated_VBN to_TO
        overexpress_NNS MDR_NNP 1_CD /_NN P-_NNP gp_NN ,_, as_RB well_RB as_IN the_DT GSTπ_NNP and_CC MRP_NNP genes_NNS ._.
        They_PRP are_VBP therefore_RB good_JJ cell_NN models_NNS for_IN studying_VBG the_DT effect_NN
        of_IN NOM_NNP on_IN breast_NN cancer_NN MDR_NNP ._.
        Semiquantitative_NNP RT-PCR_NNP analysis_NN is_VBZ a_DT sensitive_JJ and_CC
        specific_JJ method_NN [_NN 26_CD ,_, 27_CD ]_NN ._. A_DT variety_NN of_IN methods_NNS using_VBG
        either_CC quantitative_JJ or_CC semequantitative_JJ RT-PCR_NNP have_VBP been_VBN
        used_VBN to_TO determine_VB relative_JJ initial_JJ target_NN mRNA_NN levels_NNS in_IN
        samples_NNS ._. However_RB ,_, in_IN all_DT of_IN these_DT methods_NNS undefined_JJ
        variations_NNS in_IN amplification_NN complicated_VBD the_DT interpretation_NN
        of_IN results_NNS ._. Most_JJS investigators_NNS use_VBP internal_JJ amplification_NN
        standards_NNS in_IN an_DT attempt_NN to_TO correct_VB for_IN variations_NNS between_IN
        tubes_NNS ._. In_IN the_DT present_JJ study_NN ,_, as_IN in_IN many_JJ other_JJ studies_NNS ,_, we_PRP
        chose_VBD to_TO use_VB endogenous_JJ standards_NNS ._. The_DT reference_NN mRNA_NN and_CC
        target_NN mRNA_NN are_VBP usually_RB processed_VBN together_RB throughout_IN the_DT
        experiments_NNS ,_, from_IN RNA_NNP extraction_NN until_IN PCR_NNP amplification_NN ._.
        This_DT tends_VBZ to_TO minimize_VB differences_NNS in_IN RNA_NNP yields_NNS between_IN
        samples_NNS ._.
        It_PRP has_VBZ been_VBN considered_VBN that_IN the_DT overexpression_NN of_IN
        MDR_NNP 1_CD /_NN P-_NNP gp_NN is_VBZ a_DT major_JJ mechanism_NN of_IN MDR_NNP in_IN tumour_NN cells_NNS [_NN
        28_CD ]_NN ._. A_DT few_JJ studies_NNS have_VBP reported_VBN that_IN some_DT reversal_NN agents_NNS
        can_MD inhibit_VB MDR_NNP 1_CD /_NN P-_NNP gp_NN expression_NN ._. Stein_NNP 
        et_CC al_NN [_NN 29_CD ]_NN have_VBP found_VBN that_WDT cytokines_NNS
        such_JJ as_IN interleukin-_NN 2_CD ,_, interferon-γ_JJ and_CC tumour_NN necrosis_NNS
        factor-α_JJ were_VBD capable_JJ of_IN decreasing_VBG the_DT expression_NN of_IN MDR_NNP 1_CD
        mRNA_NN in_IN the_DT colon_NN carcinoma_NN cell_NN lines_NNS HCT_NNP 15_CD and_CC HCT_NNP 16_CD ._. Liu_NNP
        
        et_CC al_NN [_NN 30_CD ]_NN treated_VBD MCF_NNP 7_CD /_NN ADR_NNP cells_NNS
        with_IN the_DT Chinese_JJ herb_NN 
        Fructus_NNP psoraleae_NN for_IN 48_CD h_NN and_CC found_VBD
        that_IN P-_NNP gp_NN expression_NN became_VBD undetectable_JJ ._. However_RB ,_, no_DT
        results_NNS on_IN whether_IN or_CC not_RB progestogen_NN can_MD modulate_VBP the_DT
        expression_NN of_IN MDR_NNP 1_CD /_NN P-_NNP gp_NN have_VBP been_VBN reported_VBN ._. The_DT present_JJ
        study_NN has_VBZ demonstrated_VBN that_IN NOM_NNP significantly_RB inhibited_VBD
        MDR_NNP 1_CD /_NN P-_NNP gp_NN expression_NN on_IN the_DT third_JJ day_NN after_IN treatment_NN ._. The_DT
        MDR_NNP mRNA_NN expression_NN level_NN was_VBD very_RB low_JJ ,_, and_CC that_IN of_IN P-_NNP gp_NN
        almost_RB ceased_VBD ._.
        It_PRP is_VBZ worthy_JJ to_TO note_VB that_IN on_IN the_DT fifth_JJ day_NN after_IN NOM_NNP
        treatment_NN ,_, the_DT expression_NN of_IN MDR_NNP 1_CD /_NN P-_NNP gp_NN began_VBD to_TO increase_VB
        again_RB ._. This_DT phenomenon_NN was_VBD also_RB observed_VBN when_WRB treating_VBG
        colon_NN carcinoma_NN cell_NN line_NN with_IN cytokines_NNS [_NN 29_CD ]_NN ._. Some_DT
        studies_NNS have_VBP also_RB found_VBN that_IN P-_NNP gp_NN antagonists_NNS such_JJ as_IN VRP_NNP ,_,
        cyclosporin_NN A_DT and_CC reserpine_NN could_MD induce_VB MDR_NNP 1_CD /_NN P-_NNP gp_NN
        expression_NN in_IN the_DT colon_NN carcinoma_NN cell_NN line_NN LS_NNP 180_CD -_: Ad_NN 50_CD [_NN
        31_CD ,_, 32_CD ]_NN ._. A_DT few_JJ papers_NNS have_VBP reported_VBN MDR_NNP 1_CD expression_NN after_IN
        treatment_NN with_IN progesterone_NN ._. Lee_NNP 
        et_CC al_NN [_NN 33_CD ]_NN showed_VBD that_DT progesterone_NN
        interacted_JJ with_IN P-_NNP gp_NN ,_, inducing_VBG its_PRP$ expression_NN in_IN the_DT
        granulose_NN cell_NN in_IN preovulatory_NN follicles_NNS to_TO modulate_VBP
        steroid_NN efflux_NN ._. Our_PRP$ results_NNS show_VBP that_IN NOM_NNP modulated_JJ the_DT
        expression_NN of_IN MDR_NNP 1_CD in_IN a_DT time-dependent_JJ manner_NN ._. Over_IN 5_CD days_NNS
        of_IN treatment_NN with_IN NOM_NNP ,_, MDR_NNP 1_CD expression_NN became_VBD elevated_VBD ._.
        From_IN these_DT findings_NNS it_PRP seems_VBZ that_IN NOM_NNP and_CC other_JJ progestogen_NN
        compounds_NNS show_VBP an_DT effect_NN of_IN upregulated_JJ MDR_NNP 1_CD expression_NN in_IN
        long-term_JJ treatment_NN ._. It_PRP is_VBZ unclear_JJ how_WRB NOM_NNP effects_NNS this_DT
        time-dependent_JJ modulation_NN of_IN the_DT expression_NN of_IN MDR_NNP 1_CD /_NN P-_NNP gp_NN ._.
        If_IN a_DT similar_JJ modulation_NN of_IN the_DT MDR_NNP phenotype_NN occurs_VBZ 
        in_IN vivo_NN ,_, then_RB the_DT duration_NN of_IN
        treatment_NN with_IN NOM_NNP becomes_VBZ important_JJ ._. It_PRP will_MD be_VB of_IN prime_JJ
        importance_NN to_TO verify_VB the_DT time_NN course_NN for_IN modulation_NN by_IN
        reversal_NN agents_NNS and_CC to_TO design_VB appropriate_JJ clinical_JJ
        trials_NNS ._.
        In_IN investigating_VBG the_DT P-_NNP gp-induced_JJ MDR_NNP phenotype_NN ,_, the_DT
        overexpression_NN of_IN some_DT non-_NN P-_NNP gp_NN MDR-related_NNP proteins_NNS have_VBP
        been_VBN demonstrated_VBN ._. These_DT proteins_NNS are_VBP important_JJ in_IN drug_NN
        resistance_NN in_IN some_DT tumour_NN cell_NN lines_NNS [_NN 34_CD ,_, 35_CD ]_NN ._. We_PRP also_RB
        observed_VBD the_DT expression_NN of_IN the_DT non-_NN P-_NNP gp_NN MDR-related_NNP genes_NNS
        GSTπ_NNP ,_, TopoIIα_NNP and_CC MRP_NNP ._. We_PRP found_VBD that_IN NOM_NNP markedly_RB decreased_VBD
        the_DT level_NN of_IN expression_NN of_IN GSTπ_NNP mRNA_NN and_CC protein_NN with_IN a_DT
        time_NN course_NN similar_JJ to_TO that_DT of_IN MDR_NNP 1_CD /_NN P-_NNP gp_NN ._. The_DT results_NNS
        suggest_VBP that_IN NOM_NNP possibly_RB acts_VBZ as_IN a_DT reversal_NN agent_NN of_IN GSTπ_NNP ._.
        MRP_NNP belongs_VBZ to_TO the_DT superfamily_RB of_IN ATP-binding_NNP cassette_NN
        protein_NN transporters_NNS ._. Like_IN P-_NNP gp_NN ,_, MRP_NNP is_VBZ located_VBN in_IN the_DT
        plasma_NN membrane_NN of_IN resistant_JJ tumour_NN cells_NNS ;_: however_RB ,_, the_DT
        mechanism_NN of_IN MRP_NNP might_MD be_VB fundamentally_RB different_JJ from_IN that_DT
        of_IN P-_NNP gp_NN ._. The_DT extrusion_NN of_IN several_JJ drugs_NNS by_IN MRP_NNP requires_VBZ
        glutathione_NN ._. MRP_NNP might_MD be_VB identical_JJ to_TO the_DT GS-X_NNP pump_NN [_NN 36_CD ]_NN ._.
        MRP-related_NNP MDR_NNP was_VBD not_RB reversed_VBN by_IN classic_JJ reversal_NN agents_NNS
        of_IN P-_NNP gp_NN such_JJ as_IN VRP_NNP and_CC cyclosporin_NN A_DT [_NN 37_CD ,_, 38_CD ,_, 39_CD ]_NN ._. Our_PRP$
        results_NNS suggest_VBP that_IN NOM_NNP cannot_NN modulate_VBP MRP_NNP gene_NN
        expression_NN either_RB ._.
        TopoII_NNP ,_, as_IN a_DT kind_NN of_IN nuclease_NN ,_, is_VBZ important_JJ in_IN the_DT
        processes_NNS of_IN DNA_NNP metabolism_NN such_JJ as_IN transcription_NN ,_,
        replication_NN and_CC chromosome_NN partitioning_VBG during_IN cell_NN
        division_NN ._. TopoIIα_NNP is_VBZ present_JJ mainly_RB in_IN the_DT S_NNP phase_NN [_NN 40_CD ]_NN ._.
        TopoIIα_NNP in_IN tumour_NN cells_NNS is_VBZ a_DT target_NN enzyme_NN of_IN some_DT
        anticancer_NN agents_NNS ._. If_IN TopoIIα_NNP activity_NN decreases_NNS or_CC a_DT
        TopoIIα_NNP gene_NN mutation_NN develops_VBZ ,_, TopoIIα-related_NNP MDR_NNP results_NNS
        [_NN 41_CD ,_, 42_CD ]_NN ._.
        Our_PRP$ results_NNS showed_VBD that_IN TopoIIα_NNP expression_NN in_IN MCF_NNP 7_CD /_NN ADR_NNP
        cells_NNS was_VBD weaker_JJR than_IN in_IN MCF_NNP 7_CD /_NN WT_NNP cells_NNS ._. Because_IN TopoIIα_NNP is_VBZ
        a_DT target_NN enzyme_NN of_IN ADR_NNP ,_, MDR_NNP to_TO ADR_NNP in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS might_MD
        to_TO some_DT extent_NN be_VB related_VBN to_TO TopoIIα_NNP ._. However_RB ,_, no_DT change_NN in_IN
        TopoIIα_NNP gene_NN expression_NN level_NN was_VBD detected_VBN in_IN NOM-treated_NNP
        MCF_NNP 7_CD /_NN ADR_NNP cells_NNS ,_, indicating_VBG that_IN the_DT reversal_NN effect_NN of_IN NOM_NNP
        on_IN MDR_NNP in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS cannot_NN result_NN from_IN modulating_VBG the_DT
        gene_NN expression_NN of_IN TopoIIα_NNP ._.
        P-_NNP gp_NN belongs_VBZ to_TO the_DT ATP-dependent_NNP transporters_NNS ._. It_PRP acts_VBZ
        as_IN a_DT pump_NN or_CC hydrophobic_JJ vacuum_NN cleaner_JJR ,_, effectively_RB
        increasing_VBG drug_NN efflux_NN and_CC decreasing_VBG drug_NN influx_NN [_NN 43_CD ]_NN ._.
        Many_JJ studies_NNS have_VBP demonstrated_VBN that_IN progestogen_NN compounds_NNS
        directly_RB bind_NN P-_NNP gp_NN and_CC block_VB the_DT function_NN of_IN the_DT pump_NN
        efflux_NN [_NN 10_CD ,_, 44_CD ]_NN ._. We_PRP studied_VBD the_DT effect_NN of_IN NOM_NNP on_IN
        intracellular_NN ADR_NNP accumulation_NN in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS by_IN using_VBG
        FCM_NNP assays_NNS ._. ADR_NNP can_MD emit_NN fluorescence_NN ;_: its_PRP$ intensity_NN
        represents_VBZ its_PRP$ accumulation_NN [_NN 25_CD ]_NN ._. After_IN 2_CD h_NN of_IN treatment_NN
        with_IN NOM_NNP ,_, the_DT intracellular_NN fluorescence_NN intensity_NN of_IN ADR_NNP
        was_VBD markedly_RB enhanced_VBN ,_, suggesting_VBG that_IN NOM_NNP directly_RB
        inhibits_NNS the_DT P-_NNP gp_NN pump_NN efflux_NN function_NN in_IN the_DT same_JJ way_NN as_IN
        other_JJ progestogen_NN compounds_NNS do_VBP ._.
        It_PRP has_VBZ been_VBN reported_VBN that_IN ADR_NNP induces_VBZ dose-dependent_JJ G_NNP 
        2_CD M_NNP arrest_NN and_CC that_IN cells_NNS in_IN this_DT phase_NN
        are_VBP particularly_RB sensitive_JJ to_TO chemical_NN drugs_NNS [_NN 45_CD ]_NN ._.
        Cell-cycle_NNP DNA_NNP content_NN assays_NNS by_IN FCM_NNP suggest_VBP that_IN NOM_NNP
        enhances_VBZ the_DT blocking_VBG activity_NN of_IN ADR_NNP on_IN the_DT cell_NN cycle_NN ._.
        This_DT enhancement_NN of_IN blocking_VBG activity_NN might_MD be_VB partly_RB
        responsible_JJ for_IN the_DT reversal_NN effect_NN of_IN NOM_NNP ._.
        In_IN brief_JJ ,_, our_PRP$ results_NNS indicate_VBP that_IN in_IN MCF_NNP 7_CD /_NN ADR_NNP cells_NNS
        NOM_NNP can_MD significantly_RB sensitize_VB their_PRP$ chemosensitivity_NN to_TO
        ADR_NNP ,_, down-regulate_JJ MDR_NNP 1_CD /_NN P-_NNP gp_NN and_CC GSTπ_NNP expression_NN levels_NNS in_IN
        time-dependent_JJ manner_NN ,_, markedly_RB increase_NN intracellular_NN ADR_NNP
        accumulation_NN and_CC enhance_VB the_DT cell_NN cycle_NN blocking_VBG activity_NN
        of_IN ADR_NNP ._. At_IN present_JJ ,_, although_IN a_DT variety_NN of_IN agents_NNS inhibit_VBP
        the_DT function_NN of_IN P-_NNP gp_NN 
        in_IN vitro_NN ,_, their_PRP$ clinical_JJ use_NN is_VBZ also_RB
        limited_VBN by_IN the_DT toxicity_NN associated_VBN with_IN the_DT doses_NNS required_VBN
        to_TO reverse_VB MDR_NNP ._. Because_IN NOM_NNP can_MD be_VB safely_RB administered_VBN at_IN
        high_JJ doses_NNS ,_, it_PRP might_MD be_VB a_DT good_JJ candidate_NN for_IN an_DT MDR_NNP
        reversal_NN agent_NN in_IN clinics_NNS ._.
      
      
        Abbreviations_NNP
        ADR_NNP =_SYM adriamycin_NN ;_: DRO_NNP =_SYM droloxifen_NN ;_: GSTπ_NNP =_SYM glutathione_NN
        S-_NNP transferase_NN Pi_NNP ;_: MDR_NNP =_SYM multidrug_NN resistance_NN ;_: MG_NNP =_SYM
        megestrol_NN ;_: MRP_NNP =_SYM MDR-related_NNP protein_NN ;_: MTT_NNP =_SYM
        3_CD -_: (_( 4_CD ,_, 5_CD -_: dimethylthiazol-_NN 2_CD -_: yl_NN )_) -_: 2_CD ,_, 5_CD -_: diphenyl-_NN 2_CD 
        H_NNP -_: tetrazolium_NN bromide_NN ;_: NOM_NNP =_SYM
        nomegestrol_NN ;_: PBS_NNP =_SYM phosphate-buffered_JJ saline_NN ;_: P-_NNP gp_NN =_SYM
        P-_NNP glycoprotein_NN ;_: RT-PCR_NNP =_SYM reverse_VB transcriptase_NN polymerase_NN
        chain_NN reaction_NN ;_: TAM_NNP =_SYM tamoxifen_NN ;_: TopoIIα_NNP =_SYM topoisomerase_NN
        IIα_NNP ;_: VRP_NNP =_SYM verapamil_NN ._.
      
    
  
